TABLE 2.
Comparison of CME and Peptilav testing for the type-specific serodiagnosis of HIV-1, HIV-2, and HIV-D in the prospective evaluation
| CME serodiagnosis | No. with Peptilav serodiagnosisa
|
|||
|---|---|---|---|---|
| HIV-1 | HIV-2 | HIV-D | Total | |
| HIV-1 | 106 | 0 | 47 | 153 |
| HIV-2 | 0 | 40 | 4 | 44 |
| HIV-D | 0 | 1 | 69 | 70 |
| Total | 106 | 41 | 120 | 267 |
Sera collected consecutively were tested by Peptilav and the CME strategy.